JP6093903B2 - トリプトファン代謝によって媒介される免疫抑制の阻害剤 - Google Patents

トリプトファン代謝によって媒介される免疫抑制の阻害剤 Download PDF

Info

Publication number
JP6093903B2
JP6093903B2 JP2016501035A JP2016501035A JP6093903B2 JP 6093903 B2 JP6093903 B2 JP 6093903B2 JP 2016501035 A JP2016501035 A JP 2016501035A JP 2016501035 A JP2016501035 A JP 2016501035A JP 6093903 B2 JP6093903 B2 JP 6093903B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
acceptable salt
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016501035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519056A (ja
Inventor
サンジーブ クマール，
サンジーブ クマール，
ジェシー ワルドー，
ジェシー ワルドー，
フィロス ジャイプリ，
フィロス ジャイプリ，
マリオ マウティノ，
マリオ マウティノ，
Original Assignee
ニューリンク ジェネティクス コーポレイション
ニューリンク ジェネティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50686105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6093903(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューリンク ジェネティクス コーポレイション, ニューリンク ジェネティクス コーポレイション filed Critical ニューリンク ジェネティクス コーポレイション
Publication of JP2016519056A publication Critical patent/JP2016519056A/ja
Application granted granted Critical
Publication of JP6093903B2 publication Critical patent/JP6093903B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016501035A 2013-03-14 2014-03-10 トリプトファン代謝によって媒介される免疫抑制の阻害剤 Expired - Fee Related JP6093903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784089P 2013-03-14 2013-03-14
US61/784,089 2013-03-14
PCT/US2014/022680 WO2014159248A1 (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016221202A Division JP6352368B2 (ja) 2013-03-14 2016-11-14 トリプトファン代謝によって媒介される免疫抑制の阻害剤

Publications (2)

Publication Number Publication Date
JP2016519056A JP2016519056A (ja) 2016-06-30
JP6093903B2 true JP6093903B2 (ja) 2017-03-08

Family

ID=50686105

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501035A Expired - Fee Related JP6093903B2 (ja) 2013-03-14 2014-03-10 トリプトファン代謝によって媒介される免疫抑制の阻害剤
JP2016221202A Expired - Fee Related JP6352368B2 (ja) 2013-03-14 2016-11-14 トリプトファン代謝によって媒介される免疫抑制の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016221202A Expired - Fee Related JP6352368B2 (ja) 2013-03-14 2016-11-14 トリプトファン代謝によって媒介される免疫抑制の阻害剤

Country Status (21)

Country Link
US (2) US9617272B2 (https=)
EP (2) EP2976332B1 (https=)
JP (2) JP6093903B2 (https=)
KR (1) KR20150126623A (https=)
CN (1) CN105189466A (https=)
AU (2) AU2014241079C1 (https=)
BR (1) BR112015022588A2 (https=)
CA (1) CA2902174A1 (https=)
CL (2) CL2015002649A1 (https=)
CR (1) CR20150485A (https=)
IL (1) IL241027A0 (https=)
MA (1) MA38493B1 (https=)
MX (1) MX361375B (https=)
PE (1) PE20151593A1 (https=)
PH (1) PH12015501866A1 (https=)
RU (1) RU2667509C2 (https=)
SA (1) SA515361127B1 (https=)
SG (2) SG11201507255QA (https=)
UA (1) UA118103C2 (https=)
WO (1) WO2014159248A1 (https=)
ZA (1) ZA201607948B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (https=) 2011-04-15 2018-03-17
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
CA2956465A1 (en) 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
EP3511331A1 (en) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
WO2016071293A2 (en) 2014-11-03 2016-05-12 Iomet Pharma Ltd Pharmaceutical compound
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
TWI698435B (zh) 2015-04-10 2020-07-11 英屬開曼群島商百濟神州有限公司 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶
CN108026098B (zh) 2015-04-12 2019-09-03 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
CN107849024A (zh) * 2015-05-15 2018-03-27 吉利德科学公司 具有作为吲哚胺2,3‑二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
EP4659747A2 (en) 2015-07-24 2025-12-10 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
CN110072864B (zh) 2015-12-24 2022-05-27 基因泰克公司 Tdo2抑制剂
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
US20190031665A1 (en) * 2016-02-02 2019-01-31 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
EP3418282A4 (en) * 2016-02-19 2019-01-09 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC CONNECTION AS IMMUNOMODULATOR
TW201736373A (zh) * 2016-02-19 2017-10-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 作為免疫調節劑的三並環化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
JP6948345B2 (ja) * 2016-04-29 2021-10-13 イオメット ファーマ リミテッド インドールアミン２，３−ジオキシゲナーゼ及び／又はトリプトファン−２，３−ジオキシゲナーゼの阻害薬としての新規置換イミダゾピリジン化合物
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CA3037333A1 (en) 2016-09-19 2018-03-22 University Of South Florida Method of targeting oncolytic viruses to tumors
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
JP7623784B2 (ja) 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
US10604529B2 (en) 2016-12-20 2020-03-31 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
EP3645537A1 (en) 2017-06-28 2020-05-06 Genentech, Inc. Tdo2 and ido1 inhibitors
WO2019005559A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
CN111051305A (zh) * 2017-08-22 2020-04-21 吉利德科学公司 治疗性杂环化合物
BR112020005100A2 (pt) * 2017-09-15 2020-09-15 Taiho Pharmaceutical Co., Ltd. usos de um composto inibidor de hsp90 para produzir um agente profilático e/ou terapêutico para doenças que envolvem expressão de ido e para produzir uma composição farmacêutica para tratar tumores ido-positivos
JP7306634B2 (ja) * 2017-10-19 2023-07-11 一般社団法人ファルマバレープロジェクト支援機構 Ｉｄｏ／ｔｄｏ阻害剤
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CN116574105B (zh) * 2018-09-27 2025-10-10 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516573A (de) * 1967-08-15 1971-12-15 Sandoz Ag Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
ES2323952T3 (es) * 2002-05-15 2009-07-28 Janssen Pharmaceutica Nv 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg.
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
CA2722159C (en) 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
WO2010056567A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Imidazoisoindole neuropeptide s receptor antagonists
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
JP2012037986A (ja) 2010-08-04 2012-02-23 Canon Inc 画像形成装置及びその制御方法と画像形成システム
NO2694640T3 (https=) 2011-04-15 2018-03-17

Also Published As

Publication number Publication date
US9981973B2 (en) 2018-05-29
US20160060266A1 (en) 2016-03-03
AU2014241079A1 (en) 2015-09-03
CA2902174A1 (en) 2014-10-02
US20170260188A1 (en) 2017-09-14
ZA201607948B (en) 2018-05-30
CL2016001940A1 (es) 2017-03-10
JP6352368B2 (ja) 2018-07-04
BR112015022588A2 (pt) 2017-07-18
MX2015011385A (es) 2016-02-03
JP2016519056A (ja) 2016-06-30
HK1213259A1 (en) 2016-06-30
RU2667509C2 (ru) 2018-09-21
MA38493B1 (fr) 2017-10-31
SA515361127B1 (ar) 2017-10-19
CL2015002649A1 (es) 2016-07-29
PE20151593A1 (es) 2015-11-05
AU2017201693A1 (en) 2017-03-30
SG10201707545XA (en) 2017-10-30
MA38493A1 (fr) 2017-02-28
WO2014159248A1 (en) 2014-10-02
PH12015501866A1 (en) 2015-12-07
KR20150126623A (ko) 2015-11-12
CR20150485A (es) 2015-11-26
UA118103C2 (uk) 2018-11-26
AU2014241079B2 (en) 2016-12-15
US9617272B2 (en) 2017-04-11
EP3366678A1 (en) 2018-08-29
AU2014241079B9 (en) 2017-04-06
EP2976332B1 (en) 2018-01-31
AU2014241079C1 (en) 2017-07-06
EP2976332A1 (en) 2016-01-27
SG11201507255QA (en) 2015-10-29
IL241027A0 (en) 2015-11-30
RU2015143990A (ru) 2017-04-19
JP2017052786A (ja) 2017-03-16
MX361375B (es) 2018-12-05
CN105189466A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
JP6352368B2 (ja) トリプトファン代謝によって媒介される免疫抑制の阻害剤
KR102164443B1 (ko) Ｉｄｏ 억제제로서 유용한 융합된 이미다졸 유도체
CN107108556B (zh) 药用化合物
JP2011518841A (ja) Ｉｄｏ阻害剤
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
BR112015023279B1 (pt) compostos para inibição de fasn
WO2022017371A1 (zh) 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
HK1213259B (en) Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization.
CN118436643A (zh) Zak抑制剂在靶向肿瘤中的治疗策略及其应用
HK40004096B (zh) 1h-咪唑[4，5-h]喹唑啉类化合物作为蛋白激酶抑制剂
HK1223371B (en) Fused imidazole derivatives useful as ido inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170213

R150 Certificate of patent or registration of utility model

Ref document number: 6093903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees